Abstract Reliable tools for objective response assessment are essential in pleural mesothelioma treated with immunotherapy. We report on a 75‐year‐old man with sarcomatoid pleural mesothelioma who received a reduced nivolumab dose after developing a hypersensitivity reaction during the first infusion. CT, 18 FFDG PET/CT and 68 GaGa‐Fibroblast activation protein inhibitor‐46 (FAPI) PET/CT were performed before and after treatment. Despite the reduced dose, the patient experienced clear clinical benefit, and follow‐up imaging demonstrated substantial morphological and metabolic improvement across all imaging modalities. This case offers an unique opportunity to directly compare response assessment across three complimentary imaging modalities.
Bentestuen et al. (Thu,) studied this question.